Westenfelder M, Daschner F, Frankenschmidt A
Infection. 1984 Jan-Feb;12(1):17-9. doi: 10.1007/BF01641018.
The pharmacokinetic properties of ceftizoxime, a new beta-lactamase-resistant cephalosporin, were investigated in 27 patients following perioperative antimicrobial prophylaxis. 2 g of ceftizoxime were injected before surgery and the concentrations measured in serum, muscle and renal tissue over a period of 30 min to 7 h. The pharmacokinetic data indicated high and long-lasting concentrations of ceftizoxime, especially in the renal tissue; this makes the drug ideal for the treatment of complicated urinary tract infections with obstruction and involvement of the renal tissue, provided the bacteria present are sensitive. The administration of 2 g i. v. every 12 h should be sufficient. In view of the high and long-lasting concentrations, it should be possible to treat uncomplicated urinary tract infections with a single dose of 2 g every 24 h. However, Enterococci, Bacteroides and Pseudomonas aeruginosa are not sufficiently sensitive to ceftizoxime and a combination with an aminoglycoside is thus indicated in the treatment of high-risk patients in the absence of bacteriological tests.
对一种新型耐β-内酰胺酶头孢菌素头孢唑肟的药代动力学特性进行了研究,研究对象为27例接受围手术期抗菌药物预防的患者。术前注射2g头孢唑肟,并在30分钟至7小时内测定血清、肌肉和肾组织中的浓度。药代动力学数据表明头孢唑肟的浓度高且持久,尤其是在肾组织中;如果存在的细菌敏感,这使得该药物成为治疗伴有梗阻和肾组织受累的复杂性尿路感染的理想药物。每12小时静脉注射2g应该足够。鉴于浓度高且持久,每24小时单剂量注射2g应该有可能治疗非复杂性尿路感染。然而,肠球菌、拟杆菌和铜绿假单胞菌对头孢唑肟不够敏感,因此在没有细菌学检测的情况下,对于高危患者的治疗,建议与氨基糖苷类药物联合使用。